Table 2 Baseline characteristics of AIS patients with IDDVT and Non-IDDVT in training cohort
Variables | Training cohort (n = 431) | ||
|---|---|---|---|
Non-IDDVT (n = 335) | IDDVT (n = 96) | P-value | |
Demographic characteristics | |||
Age (years) | 67.6 ± 12.6 | 73.4 ± 8.4 | < 0.001 |
Gender | Â | Â | 0.001 |
male, n (%) | 212 (63.3%) | 43 (44.8%) | Â |
female, n (%) | 123 (36.7%) | 53 (55.2%) | Â |
Subtype of stroke, n (%) | Â | Â | 0.248 |
Large-artery atherosclerosis | 271 (80.9%) | 69 (71.9%) | Â |
Cardioembolism | 36 (10.7%) | 18 (18.8%) | Â |
Small-artery occlusion | 2 (0.6%) | 0 | Â |
Other or undetermined | 15 (4.5%) | 5 (5.2%) | Â |
Unknown | 11 (3.3%) | 4 (4.2%) | Â |
Clinical parameters, n (%) | |||
Lower limb paralysis | 112 (33.4%) | 57 (59.4%) | < 0.001 |
Current pneumonia | 49 (14.6%) | 35 (36.5%) | < 0.001 |
Atrial fibrillation | 48 (14.3%) | 33 (34.4%) | < 0.001 |
Arterial hypertension | 256 (76.4%) | 71 (74.0%) | 0.620 |
Diabetes mellitus | 115 (34.3%) | 36 (37.5%) | 0.566 |
Current malignant tumor | 11 (3.3%) | 10 (10.4%) | 0.004 |
Current uarthritis | 15 (4.5%) | 2 (2.1%) | 0.288 |
Laboratory parameters | |||
Albumin (g/L) | 37.1 ± 4.2 | 36.4 ± 4.0 | 0.170 |
Fast blood glucose (mmol/L) | 5.9 ± 2.2 | 6.0 ± 2.4 | 0.556 |
SCr (μmol/L) | 68.0 (57.0–83.0) | 63.5 (52.0–78.2) | 0.016 |
Hcy (μmol/L) | 6.1 ± 3.8 | 6.3 ± 3.9 | 0.697 |
INR | 1.1 ± 0.3 | 1.1 ± 0.2 | 0.673 |
Fibrinogen (g/L) | 3.6 ± 1.5 | 3.6 ± 1.6 | 0.848 |
D-Dimer (mg/L) | 1.2 (0.8–2.1) | 1.8 (1.2–3.7) | < 0.001 |
CRP (mg/L) | 7.3 (3.2–18.6) | 14.6 (5.9–31.5) | 0.008 |
hs-CRP (mg/L) | 3.5 (1.0–11.8) | 8.5 (3.9–32.4) | 0.021 |
1 n (%) | |||
Anticoagulants | 101 (30.1%) | 37 (38.5%) | 0.120 |
Antiplatelet | 281 (83.9%) | 77 (80.2%) | 0.398 |
Lipid-lowering agents | 324 (96.7%) | 93 (96.9%) | 0.938 |
Thrombolysis treatment | 12 (3.6%) | 8 (8.3%) | 0.051 |